VIRX
Price:
$0.2
Market Cap:
$7.88M
Viracta Therapeutics, Inc., a precision oncology company, engages in developing drugs for the treatment of virus-associated malignancies. Its lead product candidature includes Nana-val, in combination with nanatinostat and valganciclovir that is in Phase II clinical trial for Epstein-Barr virus-positive lymphoma; and open-label Phase 2 basket trial for the treatment of various relapsed/refractory Epstein-Barr virus-positive (EBV+) lymphoma, as well as an open-label Phase 1b/2 trial for the treatment of EBV+ recurrent or metastatic nasopharyngeal carcinoma and other EBV+ solid tumors. The company's development pipeline includes vecabrutinib, a clinical-stage non-covalent ITK/BTK inhibitor and...[Read more]
Industry
Biotechnology
IPO Date
2005-09-27
Stock Exchange
NASDAQ
Ticker
VIRX
According to Viracta Therapeutics, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 12.72M. This represents a change of -68.91% compared to the average of 40.92M of the last 4 quarters.
The mean historical Enterprise Value of Viracta Therapeutics, Inc. over the last ten years is 78.86M. The current 12.72M Enterprise Value has changed 1.51% with respect to the historical average. Over the past ten years (40 quarters), VIRX's Enterprise Value was at its highest in in the September 2014 quarter at 1.51B. The Enterprise Value was at its lowest in in the March 2021 quarter at 17.37M.
Average
78.86M
Median
39.41M
Minimum
-40263402.58
Maximum
524.42M
Discovering the peaks and valleys of Viracta Therapeutics, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 138.67%
Maximum Annual Enterprise Value = 524.42M
Minimum Annual Increase = -327.23%
Minimum Annual Enterprise Value = -40263402.58
Year | Enterprise Value | Change |
---|---|---|
2023 | 35.25M | -19.06% |
2022 | 43.56M | 138.67% |
2021 | 18.25M | -145.33% |
2020 | -40263402.58 | -327.23% |
2019 | 17.72M | 104.02% |
2018 | 8.69M | -87.75% |
2017 | 70.92M | 12.01% |
2016 | 63.31M | 35.43% |
2015 | 46.75M | -91.09% |
2014 | 524.42M | -39.85% |
The current Enterprise Value of Viracta Therapeutics, Inc. (VIRX) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
32.35M
5-year avg
14.90M
10-year avg
78.86M
Viracta Therapeutics, Inc.’s Enterprise Value is greater than Vincerx Pharma, Inc. (4.98M), greater than TRACON Pharmaceuticals, Inc. (-6133696.00), less than Rallybio Corporation (25.93M), less than Tenaya Therapeutics, Inc. (147.56M), less than Lyra Therapeutics, Inc. (22.05M), less than Trevi Therapeutics, Inc. (208.91M), less than SQZ Biotechnologies Company (24.11M), greater than Protara Therapeutics, Inc. (-31165818.00), less than ALX Oncology Holdings Inc. (80.42M), less than Cabaletta Bio, Inc. (24.18M), less than EyePoint Pharmaceuticals, Inc. (707.60M), less than Biomea Fusion, Inc. (241.97M), less than X4 Pharmaceuticals, Inc. (20.60M), less than Mereo BioPharma Group plc (535.33M), less than Inozyme Pharma, Inc. (308.76M), less than Terns Pharmaceuticals, Inc. (508.25M), less than Leap Therapeutics, Inc. (62.43M), less than Bicycle Therapeutics plc (733.79M), less than IGM Biosciences, Inc. (902.82M), less than Monte Rosa Therapeutics, Inc. (478.04M), less than Stoke Therapeutics, Inc. (501.96M),
Company | Enterprise Value | Market cap |
---|---|---|
4.98M | $11.06M | |
-6133696.00 | $136.30K | |
25.93M | $42.32M | |
147.56M | $190.12M | |
22.05M | $17.21M | |
208.91M | $220.68M | |
24.11M | $12.83M | |
-31165818.00 | $53.43M | |
80.42M | $78.48M | |
24.18M | $195.39M | |
707.60M | $775.07M | |
241.97M | $320.35M | |
20.60M | $89.59M | |
535.33M | $616.59M | |
308.76M | $277.29M | |
508.25M | $599.50M | |
62.43M | $140.43M | |
733.79M | $1.62B | |
902.82M | $930.71M | |
478.04M | $542.54M | |
501.96M | $689.69M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Viracta Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Viracta Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Enterprise Value?
How can you use the Enterprise Value?
What is Viracta Therapeutics, Inc.'s Enterprise Value?
What is the highest Enterprise Value for Viracta Therapeutics, Inc. (VIRX)?
What is the 3-year average Enterprise Value for Viracta Therapeutics, Inc. (VIRX)?
What is the 5-year average Enterprise Value for Viracta Therapeutics, Inc. (VIRX)?
How does the current Enterprise Value for Viracta Therapeutics, Inc. (VIRX) compare to its historical average?